BeiGene beefs up PD-1 data with positive PhIII results for tislelizumab, this time in metastatic NSCLC
BeiGene has been angling to disrupt the PD-1 market for quite some time, and on Tuesday appeared to take one step closer.
The Chinese …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
